'Practically impossible': On the difficulties of introducing new medicines across all 27 EU member states
Timely and equitable access to new medicines across all 27 EU member states has been near the top of every list for the European Commission in describing what it wants to achieve with the overhaul of its 20-year-old pharma legislation.
The only problem is that bridging that gap in access is going to be a Herculean task as currently, Eastern European countries like Latvia, Lithuania and others only see a small fraction of the new drugs that launch across other, wealthier countries like Germany and Austria.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.